A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

NCT06158490 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-severe Atopic Dermatitis

Interventions

DRUG: JYP0061 15 mg
DRUG: JYP0061 30 mg
DRUG: Placebo

Sponsor

Guangzhou JOYO Pharma Co., Ltd